Gilead's Breast Cancer Drug Gets U.S. FDA Approval for Third Indication

Per Reuters, Gilead Sciences shared FDA has approved the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.

The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies.

Sales of the drug, already approved for a type of breast and bladder cancer in the United States, nearly doubled to $680 million in 2022 from $380 million a year earlier. Analysts on average expect Trodelvy sales to reach $955.3 million in 2023, according to Refinitiv.